ABLi Therapeutics Strengthens Board with Neurodegeneration Expert Dr. Rachelle Doody Ahead of Phase 3 Trials
核心洞察
ABLi Therapeutics (搜索) has appointed Dr. Rachelle S. Doody, a veteran neurodegeneration drug developer with over 10 years of pharmaceutical leadership experience, to its Board of Directors.
Dr. Doody previously served as Global Head of Neurodegeneration at Roche, where she led development of multiple monoclonal antibodies and antisense oligonucleotides for Alzheimer's, Huntington's, and Parkinson's diseases.
The appointment comes as ABLi prepares to launch Phase 3 programs for its lead candidate risvodetinib in Parkinson's disease (搜索), Multiple System Atrophy (搜索), and Dementia with Lewy Body (搜索).
ABLi Therapeutics (搜索) announced the appointment of Dr. Rachelle S. Doody, a world-renowned expert in neurodegeneration therapeutics development, to its Board of Directors as the biotechnology company prepares to advance its lead candidate risvodetinib into Phase 3 trials for multiple neurodegenerative diseases.
Dr. Doody brings over 10 years of pharmaceutical leadership experience in clinical development of therapeutics targeting neurodegenerative diseases, including Alzheimer's and Parkinson's disease (搜索). Her appointment strengthens ABLi's leadership as the company prepares to launch Phase 3 programs for Parkinson's disease, Multiple System Atrophy (搜索) (MSA), and Dementia with Lewy Body (搜索) (DLB).
Extensive Experience in Neurodegeneration Drug Development
During her tenure as Global Head of Neurodegeneration in late-stage Neuroscience at F. Hoffman-LaRoche (搜索) (Roche), Dr. Doody led the development of several high-profile therapeutic programs. She oversaw the development of monoclonal antibodies Crenezumab and Gantenerumab for familial and sporadic Alzheimer's disease (搜索), and led late-stage development for Tominersin (搜索), an antisense oligonucleotide for Huntington's disease (搜索).
Notably, Dr. Doody also led the late-stage development program for Prasinezumab, an anti-alpha synuclein (搜索) monoclonal antibody for Parkinson's disease (搜索) that is currently in Phase 3 development. After leaving Roche in 2024, she joined biotechnology company Axxium Life (搜索) as Chief Medical Officer and Director of Development, where she oversees a pipeline of active immunotherapy medications directed against chronic and neurodegenerative diseases.
Prior to her industry career, Dr. Doody held the Effie Marie Cain Chair in Alzheimer's Disease (搜索) research at Baylor College of Medicine and is presently a Distinguished Emeritus Professor in Neurology. She completed her medical training at McGill University and did her neurology residency at Baylor, where she developed her expertise in Alzheimer's disease. Her PhD work in cognitive anthropology was completed at Rice University.
Strategic Timing for Phase 3 Preparations
"The appointment of Dr. Doody brings to the ABLi Board an industry leader in the development of neurodegenerative disease therapeutics," said Dr. Milton Werner, ABLi's Chairman and Chief Executive Officer. "Dr. Doody will advise the company on management best practices and clinical trial design as we prepare to launch our Phase 3 programs for Parkinson's, Multiple System Atrophy (搜索) (MSA) and Dementia with Lewy Body (搜索) (DLB)."
Dr. Doody expressed her commitment to advancing treatments for underserved patient populations. "Patients with neurodegenerative diseases need more and better treatments than what is available today. I am pleased to join the Board at ABLi to extend my assistance to another promising biotechnology company with the potential to really impact the synucleinopathies, such as Parkinson's disease (搜索), MSA and DLB."
Breakthrough Results with Risvodetinib
ABLi's lead candidate, risvodetinib (ABLi-148009), is a potent, selective small-molecule inhibitor of the non-receptor c-Abl kinases (搜索), designed for once-daily oral use. The drug targets the underlying biological mechanisms driving Parkinson's disease (搜索) initiation and progression, addressing a significant unmet medical need since all currently marketed therapeutic approaches only help manage symptoms without slowing or stopping disease progression.
Risvodetinib has demonstrated the ability to modify the Parkinson's disease (搜索) pathophysiologic pathway and impact neurodegenerative and neuroinflammatory disease processes in humans. In a significant clinical milestone, risvodetinib recently became the first monotherapy to improve patient quality of life in a randomized, placebo-controlled clinical trial (NCT05424276) while simultaneously reducing underlying disease pathology and suppressing the underlying disease process in patients with untreated Parkinson's disease.
Targeting Abelson Tyrosine Kinases
ABLi Therapeutics (搜索) applies innovative medicinal chemistry and deep understanding of disease biology to develop small molecule therapeutics targeting diseases that arise from activation or dysfunction of the Abelson Tyrosine Kinases (搜索) (c-Abl). The company leverages clinically validated data of kinase inhibitors to design novel product candidates with enhanced brain penetration, greater potency and target selectivity, and improved safety profiles.
The company's primary focus centers on developing therapeutics for neurodegenerative diseases like Parkinson's disease (搜索) and related conditions including Multiple System Atrophy (搜索) and Dementia with Lewy Body (搜索), all of which are associated with Abl kinase activation or dysfunction. Risvodetinib currently has intellectual property protection extending beyond 2036.